TECHNICAL SPECIFICATIONS

Drug / Excipient	
Drug	Sirolimus
Drug Dose	0.7 µg/mm^2
Drug Carrier	Customized biodegradable polymer matrix
Stent	
Stent Material	L605 Cobalt Chromium Alloy
Strut Thickness	73 µm
Strut Width	80 µm (hinge) - 120µm (strut)

Delivery System	
Delivery System	RX/Monorail
Nominal Pressure	8 Bar
Rated Burst Pressure	14 Bar*
Guidewire Compatibility (max)	0.014"
Guiding Catheter Compatibility	5F
Crossing Profile**	0.038"
Tip Entry Profile	0.016"

* Do not exceed RBP
** Reference diameter of 3.00 mm

ORDERING INFORMATION

Stent Dia (mm)	Stent Length (mm)											
	08	12	16	20	24	28	32	36	40	44	48	52
2.25	EAB22508	EAB22512	EAB22516	EAB22520	EAB22524	EAB22528	EAB22532	EAB22536	EAB22540	-	-	-
2.50	EAB25008	EAB25012	EAB25016	EAB25020	EAB25024	EAB25028	EAB25032	EAB25036	EAB25040	EAB25044	EAB25048	EAB25052
2.75	EAB27508	EAB27512	EAB27516	EAB27520	EAB27524	EAB27528	EAB27532	EAB27536	EAB27540	-	-	-
3.00	EAB30008	EAB30012	EAB30016	EAB30020	EAB30024	EAB30028	EAB30032	EAB30036	EAB30040	EAB30044	EAB30048	EAB30052
3.50	EAB35008	EAB35012	EAB35016	EAB35020	EAB35024	EAB35028	EAB35032	EAB35036	EAB35040	EAB35044	EAB35048	EAB35052
4.00	EAB40008	EAB40012	EAB40016	EAB40020	EAB40024	EAB40028	EAB40032	EAB40036	EAB40040	EAB40044	EAB40048	EAB40052
4.50	EAB45008	EAB45012	EAB45016	EAB45020	-	-	-	-	-	-	-	-
5.00	EAB50008	EAB50012	EAB50016	EAB50020	-	-	-	-	-	-	-	-



*The above diagram is just an illustration of the product.
Disclaimer: The law restricts these devices to sale by or on the order of a physician. Indications, contradictions, warnings can be found in the product labelling / IFU supplied with each device. For restricted use only in countries where product is registered with applicable health authorities.

CE 1434

ENVISION SCIENTIFIC
A Concept Medical Group Company

contact@espl.net.in www.espl.net.in /conceptmedicals

Scan for more details

ES.ST.AB.BRO.ver.1.1.21-05

ENVISION SCIENTIFIC
A Concept Medical Group Company

ABLUMINUS

SIROLIMUS ELUTING CORONARY STENT SYSTEM

DES + DCB* = DES+
*drug coating on exposed parts of balloon

Approved Indication for DM and AMI

ABLUMINUS

DIABETES MELLITUS

- Patients with DM are more affected by coronary artery disease and when treated by PCI with stent implantation they remain at higher risk of in-stent restenosis and adverse cardiovascular events. [1-3]
- The etiology of this failure is likely to be multifactorial such as diffuse disease progression, small vessel and endothelial dysfunction. [4-9]
- The presence of DM (particularly insulin-treated DM) has been a consistent, independent predictor of in-stent restenosis. [10]

STENT COMPARISON*



* GG Stefanini, M Taniwaki, S Windecker, Coronary stents: novel development, Heart doi:10.1136/heartjnl-2012-303522; I Meredith, Scientific symposium, TCT 2013; M Rothman, presentation TCT 2014



CELL DESIGN



Labelled Diameter
2.25 mm
2.50 mm
Side Branch Access
4.00 mm

6 Cell Design



Labelled Diameter
2.75 mm
3.00 mm
3.50 mm
Side Branch Access
5.30 mm

8 Cell Design



Labelled Diameter
4.00 mm
4.50 mm
5.00 mm
Side Branch Access
6.70 mm

10 Cell Design

ENVISOLUTION TECHNOLOGY

ABLUMINAL COATING
Facilitates mono directional drug release and less systemic exposure of drug leading to faster re-endothelialisation

FUSION COATING
Coating on the stent and exposed parts of the balloon facilitate homogeneous drug delivery which addresses diffused proliferative disease and focal restenosis

EDGE COATING
Additional 0.5 mm coating beyond the proximal and distal edge of the Stent addresses the edge restenosis

BIODEGRADABLE FILM
The formation of hypothetical circular film with biodegradable polymer due to elasticity of polymer facilitate maximum surface area for drug delivery in blood wet conditions



DES + DCB* = DES+
Designed to treat diabetic patients
*drug coating on exposed parts of balloon

References:
1. Kereiakes DJ et al. J Am Coll Cardiol 2010; 56: 2084-9. | 2. Cutlip DE et. al. Circulation 2004; 110: 1226-30. | 3. Lee TT et all Am J Cardiol 2006; 98:718-21. | 4. Morgan KP et al. Heart 2004; 90: 732-8. | 5. Hadi H a R et al. Vasc Health Risk Manag 2007; 3:853-76. | 6. Schalkwijk CG et. Al Clin Sci 2005; 109: 143-59. | 7. Dangas GD et al. J. Am. Coll. Cardiol. 2010; 56:1897-907. | 8. Lightell DJ et al. Ochsner J 2013; 13:56-60. | 9. Denardo SJ et al. JAMA 2012; 307:2148-50. | 10. Popma, J.J. et al. Circulation 110, 3773-3780 (2004).